Table 1. Baseline characteristics of the study population.
| Parameters | All patients (n = 92) | SVR (n = 64, 69.6%) | Non-SVR (n = 28, 30.4%) | P value* |
|---|---|---|---|---|
| Age, yr | 51.4 ± 1.2 | 49.6 ± 13.0 | 55.6 ± 7.7 | 0.007 |
| Male | 41 (44.6) | 28 (43.8) | 13 (46.4) | 0.824 |
| Cirrhosis, clinically diagnosed | 11 (12.0) | 2 (3.1) | 9 (32.1) | < 0.001 |
| HCV Genotype (1/2) | 56/36 | 34/30 | 22/6 | 0.036 |
| HCV RNA, log10IU/mL | 5.96 ± 0.07 | 5.88 ± 0.79 | 6.13 ± 0.40 | 0.045 |
| HCV Ag, log10fmol/L | 2.94 ± 0.11 | 2.80 ± 1.14 | 3.27 ± 0.76 | 0.023 |
| Serum albumin, g/dL | 4.33 ± 0.04 | 4.36 ± 0.39 | 4.24 ± 0.35 | 0.170 |
| Total bilirubin, mg/dL | 0.86 ± 0.04 | 0.81 ± 0.36 | 0.98 ± 0.39 | 0.052 |
| Alanine aminotransferase, IU/L | 79.5 ± 6.3 | 78.4 ± 60.2 | 82.1 ± 62.9 | 0.787 |
| Platelet count, 109/L | 175.0 ± 6.6 | 187.0 ± 60.8 | 147.8 ± 62.3 | 0.007 |
Values are expressed as median (range) or No. (%).
SVR, sustained virologic response; HCV, hepatitis C virus; HCV Ag, HCV core antigen.
*SVR vs. Non-SVR